Phosphoprotein gene of peste des petits ruminants virus: unsuitable for lineage determination

The aim of this study was to investigate the effect of isoflurane (ISO) and sevoflurane (SEVO) anesthesia on coagulation parameters in dogs. A total of 12 dogs were used in the study in two groups as ISO(n = 6) and SEVO(n = 6), which were brought to the clinic for ovariohysterectomy. Premedication was performed by the intravenous administration of 0.3 mg/kg midazolam, followed by 5 mg/kg intravenous bolus propofol infusion. This was followed by 1.5% ISO administration in the ISO group and 2% sevoflurane administration in the SEVO group for anesthesia maintenance. Before anesthesia, prothrombin time (PT), active partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen (FIB) level were measured at the 0th minute before anesthesia, at the 15th and 30th minutes during anesthesia, and at the 0th minute and the 1st hour after anesthesia. It was observed that the changes in TT, PT, APTT, and FIB level with time were not significant in the ISO and SEVO groups. It was determined that the changes in TT between the measurements in groups at the 30th minute during anesthesia and 0th minute after anesthesia were statistically significant (P less than 0.05)

Effect of isoflurane and sevoflurane anesthesia on coagulation parameters in dogs**

The aim of this study was to investigate the effect of isoflurane (ISO) and sevoflurane (SEVO) anesthesia on coagulation parameters in dogs. A total of 12 dogs were used in the study in two groups as ISO(n = 6) and SEVO(n = 6), which were brought to the clinic for ovariohysterectomy. Premedication was performed by the intravenous administration of 0.3 mg/kg midazolam, followed by 5 mg/kg intravenous bolus propofol infusion. This was followed by 1.5% ISO administration in the ISO group and 2% sevoflurane administration in the SEVO group for anesthesia maintenance. Before anesthesia, prothrombin time (PT), active partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen (FIB) level were measured at the 0th minute before anesthesia, at the 15th and 30th minutes during anesthesia, and at the 0th minute and the 1st hour after anesthesia. It was observed that the changes in TT, PT, APTT, and FIB level with time were not significant in the ISO and SEVO groups. It was determined that the changes in TT between the measurements in groups at the 30th minute during anesthesia and 0th minute after anesthesia were statistically significant (P less than 0.05)

Blood Biochemical and Hematological Study after Subacute Intravenous Injection of Gold and Silver Nanoparticles and Coadministered Gold and Silver Nanoparticles of Similar Sizes

Background. To investigate the effect of subacute intravenous administration AgNP (silver nanoparticles, 10 nm) and AuNP (gold nanoparticles, 12.8 nm) and AgNP/AuNP mixture to blood biochemistry, hematology, and platelet coagulation, subacute toxicity study was conducted. Methods. AuNP and AgNP in which their size distribution was not statistically different, mixed or separate, were injected into the caudal vein of male Sprague-Dawley rats for 4 weeks. The rats were allowed to recover for a further 4 weeks in order to examine systemic toxicity expressed in the blood biochemistry and hematology. The dose groups (5 males per group for the administration and 3 males for the recovery) consisted of 7 divisions, i.e., control, AgNP (with a low dose of 10 μg/kg/day and a high dose of 100 μg/kg/day), AuNP (with a low dose of 10 μg/kg/day and a high dose of 100 μg/kg/day), and mixed AgNP/AuNP (with a low dose of 10/10 μg/kg/day and a high dose of 100/100 μg/kg/day). Results. There were no significant dose-related changes in the hematology and blood biochemical values for the rats. Coagulation time in terms of the active partial thromboplastin time (APTT) and prothrombin time (PT) did not show any significant changes, when compared to the control group. Conclusion. The subacute injection of AuNP and AgNP or their mixture did not induce any noticeable systemic toxicity.

Acquired von Willebrand Syndrome Complicating Nephrotic Syndrome: A Case of a Patient With Membranous Nephropathy

Acquired von Willebrand syndrome (AVWS) is a rare clinical entity presenting with heterogeneous hemorrhagic manifestations, although some subsets of patients with AVWS may be asymptomatic until they are exposed to major trauma, an invasive procedure, or surgery. We herein report one such case in a 73-year-old male patient with nephrotic syndrome with a prolonged active partial thromboplastin time. We initially did not deal with this distinct abnormal clotting profile seriously, but persistent bleeding after a retroperitoneoscopic-assisted renal biopsy that allowed us to ascribe his nephrotic syndrome to membranous nephropathy fortuitously led to the discovery of concurrent AVWS. We feel that an accurate and prompt diagnosis as well as awareness of the disease remain a challenge for physicians and therefore strongly recommend the further accumulation of experiences similar to our own in a prospective manner. This report underscores the pitfalls associated with determining the bleeding risk, including an insufficient assessment and improper weighting of an abnormal clotting profile prior to the invasive procedure. Several management concerns that emerged in the current case are also discussed.

Use of Amphipathic Helical Peptides as An Anticoagulant

We have previously shown that an ideal amphipathic helical peptide of K7L15 composition (IAP) accelerates factor IXa-mediated factor X turnover and factor Xamediated prothrombin turnover in a phospholipid free system (Biochem J., 2008, 412:545). Under these conditions, IAP behaves as a phospholipid membrane allowing coagulation factors to bind and exert their actions. However, when IAP is used with in vitro assays that employ phospholipids such as an active partial thromboplastin time (aPTT), IAP paradoxically behaves as an anticoagulant by prolonging clotting times. We hypothesize that this anticoagulant effect occurs by blocking binding sites for coagulation factors on phospholipids membranes. To test this hypothesis, we employed three phopholipid-dependant coagulation assays, the aPTT, dilute PT and dilute RVV, with both low and high concentrations of phospholipids. We show that these coagulation times are prolonged by IAP in a concentration dependent manner and that this prolongation is abrogated by adding excess phospholipid, demonstrating phospholpid dependence for this inhibition. In purified tenase and prothrombinase assays, in the presence of phospholipids, IAP inhibits substrate turnover consistent with our hypothesis. To show direct binding between IAP and phospholipids, we conducted fluorescence spectroscopy experiments and show direct binding between IAP and phospholipid membranes. In summary, the above data demonstrate that IAP acts as an anticoagulant by blocking the interaction of coagulation factors with phospholipids membranes.

Blood Compatibility of Organic-Inorganic Biomedical Materials

Organic-inorganic hybrids involving Ti-O bonds were coated on stainless-steel (SUS316L)substrates. Tetraisopropoxide and titanium methacrylate triisopropoxide were employed as the major starting chemicals to provide TiO2-polydimethylsiloxane (PDMS) layers or organotitanium molecular thin layers, respectively. Fourier transform infrared spectra indicated that each layer contained Ti-O bonds in their structure. The obtained hybrid layers had little effects on the blood-clotting times such as active partial thromboplastin time and prothrombin time. In addition, the number of adhered platelet on the TiO2-PDMS layers depended on the composition, while the organotitanium molecular thin layers suppressed fibrinogen adsorption compared with coating-free SUS 316L substrate.